1. Home
  2. CAPR vs NPKI Comparison

CAPR vs NPKI Comparison

Compare CAPR & NPKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$22.51

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo NPK International Inc.

NPKI

NPK International Inc.

HOLD

Current Price

$14.45

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
NPKI
Founded
2005
1932
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CAPR
NPKI
Price
$22.51
$14.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
$41.38
$14.17
AVG Volume (30 Days)
1.0M
699.5K
Earning Date
03-18-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.38
Revenue
$11,130,509.00
$259,372,000.00
Revenue This Year
N/A
$26.96
Revenue Next Year
$17,308.50
$13.16
P/E Ratio
N/A
$38.01
Revenue Growth
N/A
25.65
52 Week Low
$4.30
$4.76
52 Week High
$40.37
$15.05

Technical Indicators

Market Signals
Indicator
CAPR
NPKI
Relative Strength Index (RSI) 49.65 52.77
Support Level $23.23 $13.46
Resistance Level $25.45 $15.05
Average True Range (ATR) 1.39 0.57
MACD -0.01 -0.04
Stochastic Oscillator 64.01 29.09

Price Performance

Historical Comparison
CAPR
NPKI

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About NPKI NPK International Inc.

NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.

Share on Social Networks: